TORONTO, April 16, 2018 /CNW/ - Organigram Holdings Inc.
(TSX VENTURE:OGI) (OTCQB:OGRMF) (the "Company" or "Organigram"), is
pleased to share details on the Company's involvement at the GMP
Securities' 2018 Cannabis Conference on April 19, 2018 at the Ritz-Carlton Hotel in
Toronto.
Organigram Chief Executive Officer Greg
Engel will provide a Company update including updates for
the Organigram facility as well as details on the Company's
domestic and international expansion plans in the second-floor
ballroom of the Ritz-Carlton Hotel from 9:20
a.m. to 9:40 a.m. on April
19.
Mr. Engel will meet for one-on-one discussions with
institutional investors throughout the day along with selected
members of Organigram senior management including recently
appointed Chief Financial Officer Paolo De
Luca and Guillermo Delmonte,
President of the Company's international division.
The GMP Securities Cannabis Conference will address key
investment themes, emerging opportunities, significant trends and
developments in the cannabis industry.
"The value of one-on-one discussions with the investment
community are invaluable, from both an investor perspective and a
company perspective. Organigram has ambitious plans moving into the
adult recreational market, and those watching the company have
questions," Engel says. "With so much noise in the space right now,
it's important for our management to seize opportunities for
personal connections."
Opportunities for one-on-one meetings with Organigram management
are extremely limited due to a high volume of inquiries following
the initial conference announcement. Interested investors should
contact their GMP Securities representative for further conference
registration information and potential for availability with the
company.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed
company whose wholly owned subsidiary, Organigram Inc., is a
licensed producer of medical marijuana in Canada. Organigram is focused on producing the
highest quality, condition specific medical marijuana for patients
in Canada. Organigram's facility
is located in Moncton, New
Brunswick and the Company is regulated by the Access to
Cannabis for Medical Purposes Regulations ("ACMPR").
Organigram has been ranked in the top ten Clean Technology
& Life Sciences Sector on the TSX Venture Exchange 50.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectations. Important factors - including the availability of
funds, consummation of definitive documentation, the results of
financing efforts, crop yields - that could cause actual results to
differ materially from the Company's expectations are disclosed in
the Company's documents filed from time to time on SEDAR (see
www.sedar.com). Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this press release. The Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE OrganiGram